Table 1.
Transposon insert element | Cancer type | Method | Animals | Ref. |
---|---|---|---|---|
T2/Onc3 | Squamous cell carcinoma, HCC | Pro-nuclear injection, knock in ES cell technology, ES cell electroporation, hybridization | C57BL/6J mice and C57BL/6J C3H hybrid mice | 20 |
T2/Onc | HCC | Pro-nuclear injection, knock in ES cell technology, hybridization | Hepatocyte-specific Alb-Cre mice, Rosa26-lsl-SB11 mice and p53-lsl-R270H mice | 29 |
T2/Onc2 | Intestinal intraepithelial neoplasia, adenocarcinoma, and adenoma | Pro-nuclear injection, knock in ES cell technology, hybridization | Rosa26-lsl-SB11 mice, Villin-Cre mice, and T2/Onc mice | 30 |
T2/Onc2 | Skin cancers | Pro-nuclear injection, hybridization | C57BL/6J × DBA/2J F2 embryos, AC heterozygous mice | 57 |
T2/Onc | Liver cancer | Pro-nuclear injection, knock in ES cell technology, hybridization | Tet-on-MYC mice, LAPtTA mice, Rosa26-SB11 mice, and T2/Onc mice | 58 |
T2/Onc2 and T2/Onc3 | Pancreatic adenocarcinoma | Pro-nuclear injection, knock in ES cell technology, hybridization | LSL-KrasG12D, Pdx1-Cre, T2Onc2, T2Onc3, and Rosa26-LSL-SB11 transgenic mice | 59 |
N-RAS | liver cancer | Hydrodynamic tail vein injection | C57BL/6J p19Arf-null mice | 62 |
H-RAS, c-Myc, shp53 | Sarcomatoid carcinoma | Subcutaneous injection | C57BL/6 female mice | 63 |
Fah, HBx, shp53 and N-RAS | HCC | Hydrodynamic tail vein injection | Fah−/− mice | 72 |
Alb, Albumin; c-Myc, v-myc avian myelocytomatosis viral oncogene homolog; CRC, colorectal cancer cell; Cre, a cyclization recombination enzyme; ES cell, embryonic stem cell; Fah, fumarylacetoacetate hydrolase gene; HCC, hepatocellular carcinoma; H-RAS, Harvey rat sarcoma virus oncogene; Kras, Kirsten rat sarcoma viral oncogene homolog; LAPtTA, a liver-specific tet-transactivator protein; lsl, loxP-stop-loxP; N-RAS, neuroblastoma ras oncogene; p19Arf, a positive regulator of the p53 tumor suppressor, and loss of Arf predisposes to a wide spectrum of tumors; Pdx1, pancreatic and duodenal homeobox 1; p53-lsl-R270H, R270H targeted point mutations of p53, which is considered as a conditional dominant negative p53 transgene; Rosa26-lsl-SB11, SB11 transposase cDNA preceded by lsl knocked into the Rosa26 locus; tet-o-MYC, tetracycline-repressible MYC transgene; shp53, a short hairpin RNA against tumor suppressor Trp53 encoding gene.